DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns

AstraZeneca

Status: Enrolling

Conditions: Lung Neoplasms

Study type: Observational

Funder types: Industry

Identifiers

NCT07109154

D133FR00224

Details and patient eligibility

About

This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records. Convenience sample, with an estimated inclusion of 200 patients treated in seven participating centers.

Eligible tumors for this project will be from patients with advanced (unresectable or metastatic) non-small cell lung carcinoma, who will start first-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026). Patients must be over 18 years old and data must be available in electronic medical records.

Medical records will be assessed to confirm patients' eligibility. Patients with localized disease amenable to local treatment, non-epithelial histology, small cell carcinoma and neuroendocrine tumor will not be eligible.

A survey will be designed targeting thoracic and generalist medical oncologists, aiming to understand the factors guiding the choice of first-line treatment regimens and to compare these insights with real-world data. The survey will be directed to Brazil, with an estimated of 200 filled files.

Enrollment: 200 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced (unresectable or metastatic) non-small cell lung carcinoma
• First-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026)
• > 18 years old
• Data available in electronic medical records.

Exclusion criteria

• Localized disease amenable to local treatment
• Non-epithelial histology
• Small cell carcinoma
• Neuroendocrine tumor
• Patients with unresectable NSCLC who underwent treatment with the PACIFIC protocol and are being followed up.